SEARCH

SEARCH BY CITATION

References

  • 1
    Eisenberg D, David RB, Ettner SL, et al. Trends in alternative medicine use in the United States. 1990–97. JAMA 1998; 280: 15691575.
  • 2
    Barnes J, Mills SY, Abbot NC, Willoughby M, Ernst E. Different standards for reporting adverse reactions to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies. Br J Clin Pharmacol 1998; 45: 496500.
  • 3
    Wheatley D. Hypericum Extract –potential in the treatment of depression. CNS Drugs 1998; 9: 431440.
  • 4
    Tonbridge, Kent. The saintly root of the problem. Chemist Druggist 1999; 249: 2226.
  • 5
    Rey JM, Walter G. Hypericum perforatum (St John's Wort) in depression: pest or blessing? MJA 1998; 169: 583586.
  • 6
    Anonymous. SJW, a herbal option for treating depression. Drugs Ther Perspectives 1999; 14.
  • 7
    Muller WE, Rolli M, Schafer C, Hafner U. Effects of Hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiat 1997; 30(Suppl): 102107.
  • 8
    Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetics and drug disposition: pharmacokinetic interaction of digoxin with a herbal extract from St John's Wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66: 338345.
  • 9
    Stevinson C, Ernst E. Safety of Hypericum in patients with depression. CNS Drugs 1999; 11: 125132.
  • 10
    Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart DSJW for depression: an overview and meta-analysis of randomised clinical trials. Br Med J 1996; 313: 253258.
  • 11
    Ernst E, Rand JI, Barns J, Stevinson C. Adverse effects profile of the herbal antidepressant St John's Wort (Hypericum perforatum L.). Eur J Clin Pharmacol 1998; 54: 589594.
  • 12
    Woelk H, Burkard G, Grinwald J. Benefits and risks of the Hypericum extract LI 160: drug monitoring study with 3250 patients. J Geriatr Psychiatry Neurol 1994; 7(Suppl 1): 534538.
  • 13
    Brockmoller J, Reum T, Bauer S, et al. Hypericum and pseudohypericum: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 1997; 30(Suppl 2): 94107.
  • 14
    Duran N, Song PS. Hypericin and its photodynamic action. Photochem Photobiol 1986; 43: 677680.
  • 15
    Araya OS, Ford EJH. An investigation of the type of photosensitization caused by the ingestion of St John's wort (Hypericum Perforatum) by calves. J Comp Pathol 1981; 91: 135141.
  • 16
    Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St John's wort and theophylline. Ann Pharmacother 1999; 33: 502.
  • 17
    Moore LB, Goodwin B, Jones SA et al. St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci 2000; 97: 75007502.
  • 18
    Kerb R, Bauer S, Brockmöller J, Roots I. Urinary 6-ß-hydroxycortisol excretion rate is affected by treatment with Hypericum extract. Eur J Clin Pharmacol 1997; 52: A186 (Abstract).
  • 19
    Roby A, Kantor E, Anderson G, St. Burstein A. St Johns Wort impact on CYP3A4 activity (Abstract). NCDEV, 39th Annual Meeting, Boca Raton, Florida, June 14, 1999.
  • 20
    Maurer A, Johne A, Bauer S, et al. Interaction of St Johns wort extract with phenoprocumon. Eur J Clin Pharmacol 1999; 55: A22.
  • 21
    Ernst E. Second thoughts about safety of SJW. Lancet 1999; 354: 20142016.
  • 22
    Yue QY, Bergquist C, Gerden B. Safety of St John's wort. Lancet 2000; 355: 576–577.
  • 23
    Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73: 6774.
  • 24
    Miners JO, Birkett DJ. Cytochrome P450 2C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525538.
  • 25
    Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute heart transplant rejection due to Saint John's wort. Lancet 2000; 355: 548549.
  • 26
    Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. Drug interaction between St John's wort and cyclosprine. Ann Pharmacother 2000; 34: 10131016.
  • 27
    Mai I, Krüger H, Budde K, et al. Hazardous pharmacokinetic interaction of Saint John's wort (hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharmacol Ther 2000; 38: 500502.
  • 28
    Breidenbach TH, Kliem V, Burg M, Radermacher J, Hoffmann MW. Profound drop in cyclosporin A whole blood trough levels caused by St John's wort (Hypericum perforatum) (letter). Transplantation 2000; 69: 22292230.
  • 29
    Watkins PB. The role of cytochromes P-450 in cyclosporine metabolism. J Am Acad Dermatol 1990; 23: 13091311.
  • 30
    Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62: 248260.
  • 31
    Ball SE, Forrester LM, Wolf CR, Bark DJ. Differences in the cytochrome P-450 isoenzymes involved in the 2-hydroxylation of oestradiol and 17 α-ethinyloestradiol relative activities of rat and human liver enzymes. Biochem J 1990; 267: 221226.
  • 32
    Shader RI, Oesterheld JR. Contraceptive effectiveness: cytochromes and induction. J Clin Psychopharmacol 2000; 20: 119121.
  • 33
    Schmider J, Greenblatt DJ, Van Moltke LL, et al. Biotransformation of mestranol to ethinyl in vitro: the role of cytochrome P-450 2C0 and metabolic inhibitors. J Clin Pharmacol 1997; 37: 193200.
  • 34
    Guengerich FP. Metabolism of 17 alpha-ethinyl estradiol in humans. Life Sci 1990; 47: 19811988.
  • 35
    Kaufeler R, Meier B, Brattstrom A. Ze 117 – Clinical efficacy and safety. Abstract Book Symposium Phyto-Pharmaka VII. Research and Clinical Applications. Berlin, 1213 October, 2001.
  • 36
    Ha RH, Chen J, Freiburghans AU, Folloth F. Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol 1995; 39: 321326.
  • 37
    Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Fallon J. Indinavir concentrations and St John's wort. Lancet 2000; 355: 547548.
  • 38
    Lantz MS, Buchalter E, Giambanco V. St John's wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol 1999; 12: 710.
  • 39
    Carillo JA, Dahl ML, Svensson O, Alm C, Rodriguez I, Bertilsson L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 1996; 60: 183 190.
  • 40
    Muller WEG, Rolli M, Schafer C, Hafner U. Effects of Hypericum extract on the expression of serotonin receptors. Geriatr Psychiatry Neurol 1994; 7(Suppl 1): 6364.
  • 41
    Barbenel DM, Yusufi B, O'Shea D, Bench CJ. Mania in a patient receiving testosterone replacement post-orchidectomy taking St John's wort and sertraline. J Psychopharmacol 2000; 14: 8486.
  • 42
    Cookson J. Side-effects of antidepressants. Br J Psychiatry 1993; 163(Suppl 20): 2024.
  • 43
    Gordon JB. SSRIs and St Johns wort: possible toxicity? Am Fam Phs 1998; 57: 950953.
  • 44
    Demmott K. St John's wort tied to serotonin syndrome. Clin Psychiatry News 1998; 26: 28.